Table 1.

 hs‐CRP and hemostatic markers in subjects with a respiratory tract Infection

	Median levels of hs‐CRP and hemostatic proteins
	T = 0	T = 1	T = 2	T = 3
hs‐CRP (mg L−1)	2.6 (1.3–3.8)	46.8 (21.2–114)*	13.9 (5.0–47.7)*	2.6 (2.2–8.0)
vWF antigen (%)	123 (82–166)	211 (157–247)*	196 (148–237)*	129 (102–195)†
F1 + 2 (pmol L−1)‡	247 (206–326)	200 (170–317)	235 (186–273)	218 (187–300)
PAP (μg L−1)	458 (347–605)	673 (438–1041)*	778 (602–1029)*	516 (404–647)
D‐Dimer (mg L−1 FEU)‡	0.32 (0.24–0.56)	0.53 (0.37–0.70)*	0.59 (0.45–0.80)*	0.55 (0.44–0.98)*
PAI‐1 (IU mL−1)	4.4 (3.1–5.2)	4.2 (3.6–5.5)	4.5 (4.0–5.3)	5.2 (4.4–5.9)†
Peak thrombin (nm)‡§	311 (269–356)	376 (335–414)*	401 (367–447)*	404 (359–432)*
Vel. Index (nm min−1)‡§	121 (73–138)	168 (141–187)*	180 (161–212)*	160 (141–202)*
ETP (nm min−1)‡§	1803 (1660–2067)	2009 (1661–2298)*	2041 (1851–2485)*	2155 (1846–2456)*
APC‐sr‡
Men (n = 6)	0.73 (0.59–1.78)	1.62 (0.99–3.65)	1.70 (1.21–3.95)	2.07 (1.40–4.60)†
Women (n = 8)	0.37 (0.05–0.67)	0.90 (0.35–1.32)*	1.26 (0.46–2.39)*	0.93 (0.43–1.60)*
Men + women	0.65 (0.26–0.78)	1.05 (0.63–2.12)*	1.60 (0.97–2.63)*	1.29 (0.74–1.98)*

Number of subjects: 15, with 11 confirmed infections in 10 subjects; infection could not be proven in 5 subjects. None of the female subjects were using hormone replacement therapy.

Numbers are medians with interquartile range (IQR) in parentheses. T = 0: baseline; T = 1: acute phase (influenza‐like illness); T = 2: 2–3 days after T = 1; T = 3: 14 days after T = 1.

hs‐CRP, high sensitive C‐reactive protein; VWF, von Willebrand factor; F1 + 2, prothrombin fragment 1 + 2; PAP, plasmin‐α₂‐antiplasmin complex; PAI, plasminogen activator inhibitor‐1; Vel. Index, velocity index; ETP, endogenous thrombin potential; APC‐sr, activated protein C‐sensitivity ratio.

*Significantly different from baseline (P < 0.05).

^†Tendency towards significant difference (P = 0.051–0.099).

^‡One patient using oral anticoagulation was excluded from the analysis.

^§Markers of thrombin generation.